In the study, patients received either 12 weeks of treatment with antibiotics and a one-time infusion of bezlotoxumab, which is designed to block the ability of a toxin to bind to cells, or they received 12 weeks of treatment with antibiotics and a placebo.
Fifteen percent of the patients in the group that received that bezlotoxumab infusion experienced a recurrent C. diff infection, compared to 25 percent of those who received just antibiotics and the placebo.
Following the study, Merck & Co. announced plans to file for regulatory approval of bezlotoxumab, before the end of the year. Merck & Co. licensed the antibody from Massachusetts Biologic Laboratories and Medarex, now owned by Bristol-Myers Squibb.
More articles on C. diff:
C. diff pesticide found ineffective, EPA takes action
Abnormal vitals and blood tests linked to C. diff complications
C. diff is over diagnosed by popular molecular tests, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
